0000885590-13-000062.txt : 20130730
0000885590-13-000062.hdr.sgml : 20130730
20130730175307
ACCESSION NUMBER: 0000885590-13-000062
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130726
FILED AS OF DATE: 20130730
DATE AS OF CHANGE: 20130730
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc.
CENTRAL INDEX KEY: 0000885590
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
BUSINESS PHONE: 514-744-6792
MAIL ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL Corp
DATE OF NAME CHANGE: 20100416
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL
DATE OF NAME CHANGE: 19960522
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Weldon Ryan
CENTRAL INDEX KEY: 0001564233
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14956
FILM NUMBER: 13996986
MAIL ADDRESS:
STREET 1: 4787 LEVY STREET
CITY: MONTREAL
STATE: A8
ZIP: H4R 2P9
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2013-07-26
0
0000885590
Valeant Pharmaceuticals International, Inc.
VRX
0001564233
Weldon Ryan
2150 ST. ELZEAR BLVD. WEST
LAVAL
A8
H7L 4A8
QUEBEC, CANADA
0
1
0
0
EVP, Company Group Chairman
Common Stock, no par value
2013-07-26
4
M
0
5173
0
A
68611
D
Common Stock, no par value
2013-07-26
4
F
0
2683
0
D
65928
D
Restricted Share Units
2013-07-26
4
M
0
5173
0
D
Common Stock
5173
15521
D
This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $26.51 starting on September 28, 2010 and the average stock price for the 20 trading days starting on each measurement dates: 25% on June 28, 2013, 50% on September 28, 2013 and 25% on December 28, 2013. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSUs have already paid out for the first two of the three potential shares of common stock.
This number represents common shares purchased by the officer, common shares received upon settlement and/or exercise of previously granted equity awards, as well as other outstanding equity awards that were previously reported in Table 1.
This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Performance Share Units.
by: Nicholas Zanoni for Ryan Weldon
2013-07-30